NASDAQ: NGNE 31.15%
Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy
NASDAQ: BWIN 28.55%
Baldwin (BWIN) Q4 2025 Earnings Call Transcript
NYSE: KORE 77.39%
KORE Reports Third Quarter 2025 Results
OTC: ACXIF 21.95%
Underperform Recommendation Issued On ACXIF By RBC Capital
NASDAQ: PRAA 32.17%
PRA Group (PRAA) Q4 2025 Earnings Call Transcript
NASDAQ: ENSC 73.31%
Expected US Company Earnings on Tuesday, November 11th, 2025
NASDAQ: NGNE 28.55%
NASDAQ: KORE 28.55%
NASDAQ: ACXIF 28.55%
NASDAQ: PRAA 28.55%
